deltatrials
Unknown PHASE4 INTERVENTIONAL 2-arm NCT02764515

Kunxian for the Treatment of Rheumatoid Arthritis

Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis

Sponsor: CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group

Conditions Rheumatoid Arthritis
Interventions Kunxian Capsule Methotrexate
Updated 7 times since 2017 Last updated: Mar 8, 2017 Started: Sep 30, 2015 Primary completion: Sep 30, 2017 Completion: Nov 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Rheumatoid Arthritis and is currently ongoing. CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotRecruiting~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE4

  5. Apr 2019 — Jan 2021 [monthly]

    Unknown Status PHASE4

    Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

  1. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE4

  2. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group
  • CHINESE RHEUMATISM DATA CENTER
  • Chinese SLE Treatment And Research Group
Data source: Chinese SLE Treatment And Research Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Bengbu, China , Enshi, China , Guangzhou, China , Haerbin, China , Hefei, China , Kunming, China , Nanjing, China , Nantong, China , Shanghai, China and 2 more locations